Phathom Pharmaceuticals, Inc. — Form 8-K Summary
Business context and reporting period
Phathom Pharmaceuticals, Inc. filed a Form 8-K dated May 10, 2023, under Item 2.02 to announce financial results for the quarter ended March 31, 2023. The filing references an attached May 10, 2023 press release as Exhibit 99.1, but the press release text is not included in the provided filing content.
Financial metrics
The provided filing text does not state clear values for revenue, net income or loss, cash flow, operating expenses, margins, debt, cash, liquidity, or other financial metrics.
Material changes versus the prior comparable period
The filing does not provide comparative financial data or describe material changes versus the prior-year or prior-quarter period.
Guidance, outlook, risks, and unusual items
The provided text does not include management guidance, outlook commentary, risk updates, contingencies, or unusual items. It only states that the company issued a press release announcing quarterly financial results.
Investor verification points
- Review Exhibit 99.1 for the actual March 31, 2023 financial results and year-over-year comparisons.
- Verify reported cash, cash equivalents, liquidity runway, operating cash burn, debt, and financing activities.
- Check for management guidance, clinical or regulatory updates, and any disclosed risks or contingencies in the press release.
- Note that the Form 8-K states the information, including Exhibit 99.1, is furnished rather than filed for purposes of Exchange Act Section 18 liability, except where incorporated by specific reference.